FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:196-197 January 15, 1998 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Hammer, S. M.

To the Editor: With respect to the report by Hammer et al. (Sept. 11 issue),¹ we are troubled by the randomization of patients with human immunodeficiency virus (HIV) infection and CD4 cell counts of 50 or fewer per cubic millimeter to a group without a protease inhibitor. Data indicating that the addition of ritonavir to the regimens of patients who have received antiretroviral therapy reduces AIDS-defining events and mortality had been reported at two international meetings^2,3 and reviewed by the Food and Drug Administration's Antiviral Drugs Advisory Committee before closure of the randomization period and the first review. Was demonstrating . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.